In a more recent study regarding HFpEF, the Prospective Comparison of angiotensin receptor–neprilysin inhibitor with angiotensin-receptor blockers Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial, 54% of patients with HFpEF had both prior AF and AF at enrollment. This evidence concerns the gene MME and atrial fibrillation.